Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2019

View Archived Issues

Umbralisib plus ibrutinib demonstrate safety and activity in patients with leukemia and lymphoma

Methylscape alteration of DNA physicochemical properties can be applied for cancer diagnostic assays

Discovery of osimertinib analogue that selectively inhibits EGFR for NSCLC treatment

Novel selective azaindole TGF-beta receptor kinase inhibitors may improve immuno-oncology therapy

AOH-1160 demonstrates promising anticancer activity without significant toxicity in vivo

Sleeping sickness parasite can make its own sugar

Genetic diversity makes for better Alzheimer's model

ST-8116 demonstrates promising antitumor activity in preclinical models of colon cancer

Epigenetic analysis boosts malaria pathogenesis understanding

Patient enrollment ongoing in phase I study of BOS-172738

NicOx presents new compounds for eye disorders

Chiesi Farmaceutici patents new MAPK 14 inhibitors

Cadila Healthcare synthesizes NLRP3 inhibitors

Hanmi Science describes KDM1A inhibitors

Dosing begins in phase III study of Tyvyt for first-line esophageal squamous cell carcinoma

New PDE9 inhibitors presented by Merck & Co.

ALCAM-EGFR axis discovered as therapeutic target in multiple myeloma

BioCryst doses first patient in phase I trial of intravenous galidesivir

Cybrexa selects CBX-11 as lead clinical development candidate

Arcturus Therapeutics nominates ARCT-810 as development candidate for OTC deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....